glucagon

Glucagon (19-29), human acetate a COOH-terminal fragment processed from glucagon, is a potent and efficient inhibitor of insulin secretion.

Glucagon is a 29-amino-acid peptide hormone liberated in the alpha cells of the islets of Langerhans. Glucagon-producing alpha cells represent one of the earliest populations of detectable islet cells in the developing endocrine pancreas.

Glucagon-like peptide 1 (1-37), human is a highly potent agonist of the GLP-1 receptor.Pancreatic hormone synthesized by post-translational processing of proglucagon. Unlike truncated forms of GLP-1, it has no effect on food intake in rats and does not en

(Met(O)27)-Glucagon (1-29) (human, rat, porcine) is a modified version of glucagon that exhibits the same maximum glucose-synthesizing activity in rat hepatocytes as its native counterpart. However, its reduced potency indicates the importance of methionine in glucagon's attachment to hepatic receptors [1].

Glucagon (22-29) acts as a partial agonist of Glucagon (19–29) and independently inhibits the calcium (Ca2+) pump in liver plasma membranes without activating adenylate cyclase [1] [2].

(Asp28)-Glucagon (1-29) (human, rat, porcine) is an analog of glucagon with an aspartic acid (Asp) substitution at position 28, notably enhancing its aqueous solubility at physiological pH levels while retaining glucagon's innate biological activity [1].

Glucagon-like peptide 1 (1-37), human acetate is a highly potent the GLP-1 receptor agonist.

Glucagon is a peptide hormone, produced by pancreatic α-cells. Glucagon reduces the activity of HNF-4. Glucagon stimulates gluconeogenesis. Glucagon enhances HNF4α phosphorylation.

Biotinyl-Glucagon (1-29), encompassing human, bovine, and porcine versions, is a biotinylated form of glucagon. This peptide hormone, synthesized by the pancreas's α-cells, elevates glucose and fatty acid levels in the bloodstream [1] [2].

Glucagon receptor antagonist (pA2 = 7.2 for inhibition of glucagon-induced adenylyl cyclase activation in rat liver membranes); displays no agonist activity. Enhances glucose-stimulated pancreatic insulin release in vitro. Blocks added glucagon-induced hy

Glucagon-like peptide 1 (1-37), human (TFA) is a highly potent agonist of the GLP-1 receptor, it is a kind of pancreatic hormone synthesized by post-translational processing of proglucagon.

Glucagon-Like Peptide 1 (GLP-1) (7-36)-Lys (Biotin), amide, human, is a human GLP-1 (7-36) amide that has been biotinylated at the C-terminal.

[Des-His1,Glu9] Glucagon, a powerful antagonist of the glucagon receptor system, plays a crucial role in enhancing the glucose-stimulated insulin release from pancreatic islet cells. This compound is utilized in diabetes research [1].

Glucagon-like peptide 2 (GLP-2) is a recently identified intestinal epithelium-specific growth factor that has been shown to reduce the severity of inflammatory disorders of the intestine in rodent models. Currently Glucagon-Like Peptide 2 is used as a po

Human glucagon-like peptide-1-(7-36)-Lys(Biotin) amide, a biotin-labeled variant of glucagon-like peptide-1-(7-36), is a gastrointestinal peptide recognized for its antidiabetogenic properties, including the ability to enhance insulin secretion [1] [2].

[Des-His1,Glu9]-Glucagon amide TFA is a potent peptide antagonist targeting the glucagon receptor, featuring a pA2 value of 7.2. It holds potential utility in diabetes pathogenesis research[1].

Glucagon (1-29), bovine, human, porcine hydrochloride is a peptide hormone, produced by pancreatic α-cells. It activates HNF4α and increases HNF4α phosphorylation. Glucagon (1-29), bovine, human, porcine hydrochloride(Porcine glucagon hydrochloride) stimulates gluconeogenesis.

GLP-1(7-36), amide (MKC 253) is a peptide hormone released from intestinal L-cells upon nutrient consumption. It binds the GLP-1 receptor in the pancreas and displays various antidiabetic effects by potentiating glucose-induced secretion of insulin from pancreatic β-cells, increasing insulin expression.

GLP-2(1-33) (human) is an enteroendocrine hormone which stimulates the growth of the intestinal epithelium.

GLP-1 (1-36) amide (human, rat) TFA, a molecular variant of GLP-1 (7-36) amide, can induce [14C]aminopyrine accumulation in enzymatically dispersed enriched rat parietal cells [1].

GLP-1 (1-36) amide (human, rat) is a molecular variant of the GLP-1 (7-36) amide and has the capacity to stimulate [14C]aminopyrine accumulation in enzymatically dispersed, enriched rat parietal cells [1].

Oxyntomodulin (bovine, porcine) TFA is a 37-amino acid peptide hormone that functions as a glucagon-like peptide 1 (GLP-1) receptor agonist [1].

Semaglutide is a glucagon-like peptide 1 receptor (GLP-1R) agonist(EC50 of 6.2 pM in a reporter assay using BHK cells expressing the human receptor).

Liraglutide (Liraglutida) is a long-acting GLP-1 receptor agonist.

Secretin (33-59), rat (Secretin (rat)) is a classical hormone in the gastrointestinal system and a neuropeptide.

Oxyntomodulin acetate, a 37-amino acid peptide hormone, is a glucagon-like peptide 1 (GLP-1) receptor agonist[1].

Semaglutide Acetate is an agonist of a glucagon-like peptide 1 (GLP-1) receptor and can be used in studies about the treatment of type 2 diabetes.

Retatrutide sodium salt is a potent triple agonist peptide for glucagon receptor (GCGR), glucose-dependent proinsulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R) Retatrutide sodium salt is used in the study of type 2 diabetes and obesity.

Xenin 8 acetate is a biologically active fragment of Xenin in the neurotensin/xenopsin family. Xenin 8 acetate augments Arginine-induced insulin release (by 40%) and potentiates the glucagon responses to both Arginine (by 60%), Carbachol (by 50%).

Mazdutide acetate is a potent co-agonist of glucagon-like peptide (GLP-1R) and glucagon receptor (GCGR), a gastrin-regulating hormone analog.Mazdutide acetate stimulates insulin secretion from mouse pancreatic islets, and can be used in studies of obesity and type 2 diabetes (T2D).

Avexitide acetate (exendin 9-39) is a potent glucagon-like peptide 1 receptor (GLP-1R) antagonist for the study of post-obesity hypoglycemia.

Dasiglucagon acetate is a novel glucagon analog for diabetic hypoglycemia therapy. Dasiglucagon acetate has demonstrated established solubility and stability in an aqueous formulation. Pharmacokinetics studies have shown dasiglucagon acetate to exhibit hi

Exendin-4 (Exenatide) is a glucagon-like peptide-1 receptor (GLP-1) agonist (IC50: 3.22 nM). Exenatide is a 39 amino acid peptide. Compared to GLP-1, exenatide has a longer half-life of 2.4 hours.

Hylambatin, a tachykinin, elevates plasma glucose and insulin levels without altering glucagon secretion, and is utilized in diabetes research [1].

Pegloxenatide, a glucagon-like peptide-1 receptor (GLP-1 RA) agonist, is utilized in type 2 diabetes research [1].

GLP-1 receptor agonist. Endogenous preproglucagon-derived neuropeptide that modulates feeding and metabolism. Also secreted by intestinal L-cells. Increases cAMP production and inhibits gastric acid secretion in rat stomach. Also weak glucagon receptor ag

Retatrutide (LY3437943) TFA is a triple agonist peptide targeting the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Demonstrating inhibitory activity, Retatrutide TFA exhibits EC50 values of 5.79 nM for GCGR, 0.0643 nM for GIPR, and 0.775 nM for GLP-1R. It holds potential for obesity research applications [1].

Dulaglutide (LY2189265), a glucagon-like peptide-1 (GLP-1) receptor agonist, is utilized in the study of type 2 diabetes (T2D) [1] [2].

GIP, rat TFA (glucose-dependent insulinotropic polypeptide), a 42-amino acid peptide secreted by K cells in the duodenum and jejunum, promotes insulin release from pancreatic beta cells, supports beta cell proliferation, and enhances their survival. This rat-origin bioactive peptide, along with GLP (gastric-like peptide), belongs to the intestinal insulinotropic hormone family and is implicated in lipid homeostasis and potentially in the pathogenesis of obesity. Recent research suggests GIP's multifaceted role in these metabolic processes.

Somatostatin, also known as growth hormone-inhibiting hormone, is a naturally-occurring peptide hormone of 14 or 28 amino acid residues that regulates the endocrine system. It is secreted by the D cells of the islets to inhibit the release of insulin and

Tirzepatide hydrochloride (LY3298176 hydrochloride) is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist.

neurotensin-like peptide that modulate pancreatic insulin and glucagon secretion/effects

Taspoglutide is a long-acting glucagon-like peptide 1 (GLP-1) receptor agonist(EC50 value of 0.06 nM),and for treatment of type 2 diabetes

Exendin-4 (3-39) is a truncated peptide variant of Exendin-4, missing the initial two amino acids, and serves as a potent agonist for the Glucagon-like peptide-1 receptor (GLP-1r). This compound, along with Exendin-4, is utilized in the study of diabetes and hypothalamic-pituitary-adrenal (HPA) axis disorders [1] [2].

Mazdutide (IBI-362; LY-3305677), a synthetic oxyntomodulin analog, serves as a glucagon-like peptide-1 (GLP-1R)/glucagon receptor (GCGR) co-agonist. Demonstrating safety and tolerability, Mazdutide is utilized in obesity and type 2 diabetes (T2D) research [1] [2].

Teduglutide TFA, a dipeptidyl peptidase IV-resistant glucagon-like peptide-2 (GLP-2) analogue, exhibits trophic effects on the gut mucosa and is used in research related to short bowel syndrome (SBS) and Crohn's disease (CD) [1] [2].

Oxyntomodulin (human, mouse, rat) (Proglucagon [33-69]), a derivative of the glucagon progenitor, encompasses the full sequence of glucagon along with an additional C-terminal octapeptide, culminating in a structure of 37 amino acids.

NN1177, a long-acting GLP-1/glucagon receptor co-agonist, exhibits a dose-dependent reduction in body weight among diet-induced obese (DIO) mice and has potential applications in the study of weight loss and metabolic regulation [1].

FC382K10W15, a glucagon derivative, is valuable for research in diabetes [1].

Bamadutide (SAR425899) is a potent dual agonist for the glucagon-like peptide-1 receptor and glucagon receptor, which notably enhances β-cell function and decreases the rate of glucose absorption in vivo, thereby improving postprandial glucose control. This compound has potential applications in type 2 diabetes research [1].